Studies on Stercuia Gum Formulations in the Form of Osmotic Core Tablet for Colon-Specific Drug Delivery of Azathioprine

References

1. 1.↵
   1. Jain A.,
   2. Gupta Y.,
   3. Jain S. K.

   Perspectives of biodegradable natural polysaccharides for site-specific drug delivery to the colon. J. Pharm. Pharm. Sci. 2007, 10 (1), 86–128.

   OpenUrlPubMedGoogle Scholar
2. 2.↵
   1. Pantel N.,
   2. Patel J.,
   3. Gandhi T.,
   4. Shah S.

   Novel pharmaceutical approach for colon-specific drug delivery: an overview. J. Pharm. Res. 2008, 1, 2–10.

   OpenUrlGoogle Scholar
3. 3.↵
   1. Kaur K.,
   2. Kim K.

   Studies of chitosan/organic acid/Eudragit RS/RL-coated system for colonic delivery. Int. J. Pharm. 2009, 366 (1–2), 140–148.

   OpenUrlPubMedGoogle Scholar
4. 4.↵
   1. Fan L. F.,
   2. He W.,
   3. Chang Y. Z.,
   4. Xiang B.,
   5. Du Q.,
   6. Wang F.,
   7. Qin M.,
   8. Cao D. Y.

   Studies of chitosan/Kollicoat SR 30D film-coated tablets for colonic drug delivery. Int. J. Pharm. 2009, 375 (1–2), 8–15.

   OpenUrlPubMedGoogle Scholar
5. 5.↵
   1. Raghavan C. V.,
   2. Muthulingam C.,
   3. Jenita J. A.,
   4. Ravi T. K.

   An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting. Chem. Pharm. Bull. 2002, 50 (7), 892–895.

   OpenUrlPubMedGoogle Scholar
6. 6.↵
   1. Hocking G. M.

   Sterculia foetida. A Dictionary of Natural Products, 2nd ed.; Plexus Publishing Inc.: Medford, NJ, 1997; pp 754–755.

   Google Scholar
7. 7.↵
   1. Murali Mohan Babu G. V.,
   2. Prasad Ch. D.,
   3. Ramana Murthy K. V.

   Evaluation of modified gum karaya as carrier for the dissolution enhancement of poorly water-soluble drug nimodipine. Int. J. Pharm. 2002, 234 (1–2), 1–17.

   OpenUrlPubMedGoogle Scholar
8. 8.↵
   1. Lu E. X.,
   2. Jiang Z. Q.,
   3. Zang Q. Z.,
   4. Jiang X. G.

   A water-insoluble drug monolithic osmotic tablet system utilizing gum Arabic as an osmotic, suspending and expanding agent. J. Controlled Release 2003, 92 (3), 375–382.

   OpenUrlPubMedGoogle Scholar
9. 9.↵
   1. Waterman K. C.,
   2. MacDonald B. C.,
   3. Roy M. C.

   Extrudable core system: Development of a single-layer osmotic controlled-release tablet. J. Controlled Release 2009, 134 (3), 201–206.

   OpenUrlPubMedGoogle Scholar
10. 10.↵
    1. Singh B. N.,
    2. Kim K. H.

    Characterization and relevance of physicochemical interactions among components of a novel multiparticulate formulation for colonic delivery. Int. J. Pharm. 2007, 341 (1–2), 143–151.

    OpenUrlPubMedGoogle Scholar
11. 11.↵
    General Notices and Monograph, Powdered Sterculia and Sterculia Gum. British Pharmacopoeia, 34th ed.; British Pharmacopoeial Commission: London, 2009.

    Google Scholar
12. 12.↵
    1. Evans W. C.

    Pharmacognosy, 4th ed.; Elsevier Publications: New York, 2008; pp 207–208.

    Google Scholar
13. 13.↵
    1. Katsuma M.,
    2. Watanabe S.,
    3. Kawai H.,
    4. Takemura S.,
    5. Masuda Y.,
    6. Fukui M.

    Studies on lactulose formulations for colon-specific drug delivery. Int. J. Pharm. 2002, 249 (1–2), 33–43.

    OpenUrlPubMedGoogle Scholar
14. 14.↵
    1. Zhang H.,
    2. Neau S. H.

    In vitro degradation of chitosan by bacterial enzymes from rat caecal and colonic contents. Biomaterials 2002, 23 (13), 2761–2766.

    OpenUrlPubMedGoogle Scholar
15. 15.↵
    1. Kandarapu R.,
    2. Grover V.,
    3. Chawla H. P. S.,
    4. Garg S.

    Evaluation of compatibility of ketorolac tromethamine with selected polymers and common tablet excipients by thermal and isothermal stress testing. J. Pharm. Sci. 2001, 11 (6), 449–457.

    OpenUrlGoogle Scholar
16. 16.↵
    1. Verma K. R.,
    2. Garg S.

    Compatibility studies between isosorbide mononitrate and selected excipients used in the development of extended release formulations. J. Pharm. Biomed. Anal. 2004, 35 (3), 449–458.

    OpenUrlPubMedGoogle Scholar
17. 17.↵
    1. Batista de Carvalho L. A.,
    2. Marques M. P.,
    3. Tomkinson J.

    Drug–excipient interactions in ketoprofen: a vibrational spectroscopy study. Biopolymers 2006, 82 (4), 420–424.

    OpenUrlPubMedGoogle Scholar
18. 18.↵
    1. Martin A.,
    2. Sinko P. S.

    Martin's Physical Pharmacy and Pharmaceutical Sciences, 5th ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2006; pp 27–29.

    Google Scholar
19. 19.↵
    1. Gohel M. C.,
    2. Jogani P. D.

    An investigation in direct compression characteristics of co-processed lactose-starch using experimental design. Indian J. Pharm. Sci. 2003, 65 (1), 31–38.

    OpenUrlGoogle Scholar
20. 20.↵
    1. Schilling S. U.,
    2. Bruce C. D.,
    3. Shah N. H.,
    4. Malick A. W.,
    5. McGinity J. W.

    Citric acid monohydrate as a release-modifying agent in melt extruded matrix tablets. Int. J. Pharm. 2008, 361 (1–2), 158–168.

    OpenUrlPubMedGoogle Scholar
21. 21.↵
    1. Varshosaz J.,
    2. Tavakoli N.,
    3. Kheirolahi F.

    Use of hydrophilic natural gums in formulation of sustained-release matrix tablets of tramadol hydrochloride. AAPS PharmSciTech 2006, 7 (1), E168–E174.

    OpenUrlGoogle Scholar
22. 22.↵
    1. Talukdar M. M.,
    2. Kinget R.

    Swelling and drug release behavior of xanthan gum matrix tablets. Drug Dev. Ind. Pharm. 1995, 120 (1), 63–72.

    OpenUrlGoogle Scholar
23. 23.↵
    1. Yang L.

    Biorelevant dissolution testing of colon-specific delivery systems activated by colonic microflora. J. Controlled Release 2008, 125 (2), 77–86.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
24. 24.↵
    1. Ceschel G. C.,
    2. Maffei P.,
    3. Badiello R.

    Optimization of hydrochlorothiazide tablets. Drug. Dev. Ind. Pharm. 1999, 25 (11), 1167–1176.

    OpenUrlPubMedGoogle Scholar